more info, page-14

Oilburner,
There were 2 issues related to the Hepatitis C Virus nuceoside patent:
1. Awarding of the US Patent in February 2012 to Biota should have been announced to the market.
2. Biocryst challenge to the US patent should have been announced to the market rather than waiting for a sppeding ticket from the ASX.
Both were "Market Sensitive"

Currently the general market is unaware that the Lani production facility agreement has been signed with AMRI in the US other than comments on Hot Copper or the US media.
http://www.amriglobal.com/news_and_publications/news_detail.cfm?ID=221

This could open up Biota to legal liability if a shareholder(s) sold in the absence of this information.

The science is fantastic. The treatment of shareholders is appalling.

Regards
Kangaroo1